



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

August 23, 2013

Via E-mail

Mr. Blair Sorby  
Chief Executive Officer  
Resolute Oncology, Inc.  
1200 Route 22 East, Suite 2000  
Bridgewater, NJ 08807

**Re: Resolute Oncology, Inc.  
Form 10-K for the Year Ended  
December 31, 2012  
Filed March 28, 2013  
File No. 333-166848**

Dear Mr. Sorby:

We have completed our review of your filings. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filings and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filings to be certain that the filings include the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/Tia L. Jenkins

Tia L. Jenkins  
Senior Assistant Chief Accountant  
Office of Beverages, Apparel, and  
Mining